Summary of Role of Liposomal Amphotericin B in Intensive Care Unit: An Expert Opinion Paper (Bussini et al.)
Abstract Summary: Bussini et al. provide an expert opinion on the appropriate clinical use of Liposomal Amphotericin B (L-AmB) in treating invasive fungal infections (IFI) within the intensive care unit (ICU). The authors detail the limitations of current antifungal treatments, emphasizing the broad antifungal activity, favorable safety profile, and minimal drug-drug interactions of L-AmB, especially when first-line therapies are compromised by resistance or patient-specific concerns.
Key Points:
-
Clinical Context: IFIs are increasingly prevalent and life-threatening in ICU settings, driven by factors such as broad-spectrum antibiotic use, invasive procedures, immunosuppression, and comorbidities.
-
Changing Epidemiology: Although candidiasis remains predominant, an increasing incidence of non-albicans Candida species and invasive aspergillosis (IA), especially in patients without traditional risk factors, has been observed.
-
Drug Resistance Concerns: The emergence of multi-drug resistant fungi, including azole-resistant Candida spp., echinocandin-resistant species, and azole-resistant Aspergillus fumigatus, poses significant treatment challenges.
-
Advantages of L-AmB: L-AmB demonstrates broad-spectrum activity against Candida, Aspergillus, and rare molds, offering a lower nephrotoxicity risk compared to conventional amphotericin B formulations.
-
Dosage Recommendations: The recommended L-AmB dosage is typically 3-5 mg/kg/day, with higher doses (10 mg/kg/day) considered only for specific infections like cryptococcal meningitis and visceral leishmaniasis.
-
Clinical Scenarios for L-AmB Use: L-AmB is recommended particularly in scenarios involving azole-resistant infections, hepatic impairment, significant drug-drug interactions, or when therapeutic drug monitoring (TDM) for azoles is unavailable.
-
L-AmB in Solid Organ Transplantation (SOT): In SOT recipients, L-AmB can be a suitable choice due to minimal drug-drug interactions, making it an effective alternative for antifungal prophylaxis and treatment.
-
Hematologic Malignancies: L-AmB is advocated for high-risk patients, particularly those with prolonged neutropenia or breakthrough infections despite azole prophylaxis.
-
Abdominal Surgery Applications: L-AmB is considered a viable first-line treatment for severe intra-abdominal infections or septic shock, especially when non-albicans Candida species or previous echinocandin use are factors.
-
Expert Panel Methodology: A multidisciplinary expert panel formulated 35 statements to guide clinical decisions on L-AmB use, validated through external expert consensus, emphasizing tailored antifungal strategies based on patient-specific clinical and microbiological criteria.
Conclusion: Liposomal Amphotericin B represents a critical therapeutic option in ICU settings, particularly in the presence of resistant pathogens, complex drug interactions, or severe organ dysfunction. This expert opinion provides essential guidance for clinicians navigating complex antifungal treatment scenarios.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
